301 related articles for article (PubMed ID: 27601021)
21. Serum Dickkopf 1 levels in sclerostin deficiency.
van Lierop AH; Moester MJ; Hamdy NA; Papapoulos SE
J Clin Endocrinol Metab; 2014 Feb; 99(2):E252-6. PubMed ID: 24302746
[TBL] [Abstract][Full Text] [Related]
22. Circulating sclerostin and dickkopf-1 levels in ossification of the posterior longitudinal ligament of the spine.
Kashii M; Matuso Y; Sugiura T; Fujimori T; Nagamoto Y; Makino T; Kaito T; Ebina K; Iwasaki M; Yoshikawa H
J Bone Miner Metab; 2016 May; 34(3):315-24. PubMed ID: 26040409
[TBL] [Abstract][Full Text] [Related]
23. Bone turnover alterations across the menopausal transition in south-eastern Chinese women [corrected].
Ma L; Song Y; Li C; Wang E; Zheng D; Qu F; Zhou J
Climacteric; 2016 Aug; 19(4):400-5. PubMed ID: 27147201
[TBL] [Abstract][Full Text] [Related]
24. Role of sclerostin and dkk1 in bone remodeling in type 2 diabetic patients.
Wang N; Xue P; Wu X; Ma J; Wang Y; Li Y
Endocr Res; 2018 Feb; 43(1):29-38. PubMed ID: 28972408
[TBL] [Abstract][Full Text] [Related]
25. Regulation of circulating sclerostin levels by sex steroids in women and in men.
Mödder UI; Clowes JA; Hoey K; Peterson JM; McCready L; Oursler MJ; Riggs BL; Khosla S
J Bone Miner Res; 2011 Jan; 26(1):27-34. PubMed ID: 20499362
[TBL] [Abstract][Full Text] [Related]
26. Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle.
Gorai I; Taguchi Y; Chaki O; Kikuchi R; Nakayama M; Yang BC; Yokota S; Minaguchi H
J Clin Endocrinol Metab; 1998 Feb; 83(2):326-32. PubMed ID: 9467535
[TBL] [Abstract][Full Text] [Related]
27. Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases.
Kawazoe M; Kaneko K; Shikano K; Kusunoki N; Nanki T; Kawai S
Clin Rheumatol; 2018 Aug; 37(8):2169-2178. PubMed ID: 28551822
[TBL] [Abstract][Full Text] [Related]
28. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
Voskaridou E; Christoulas D; Plata E; Bratengeier C; Anastasilakis AD; Komninaka V; Kaliontzi D; Gkotzamanidou M; Polyzos SA; Dimopoulou M; Terpos E
Horm Metab Res; 2012 Nov; 44(12):909-13. PubMed ID: 22581647
[TBL] [Abstract][Full Text] [Related]
29. Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer.
Kyvernitakis I; Rachner TD; Urbschat A; Hars O; Hofbauer LC; Hadji P
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1671-80. PubMed ID: 24903965
[TBL] [Abstract][Full Text] [Related]
30. Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes.
Brabnikova Maresova K; Pavelka K; Stepan JJ
Calcif Tissue Int; 2013 Apr; 92(4):354-61. PubMed ID: 23247536
[TBL] [Abstract][Full Text] [Related]
31. Menstrual Cycle Related Fluctuations in Circulating Markers of Bone Metabolism at Rest and in Response to Running in Eumenorrheic Females.
Guzman A; Kurgan N; Moniz SC; McCarthy SF; Sale C; Logan-Sprenger H; Elliott-Sale KJ; Hazell TJ; Klentrou P
Calcif Tissue Int; 2022 Aug; 111(2):124-136. PubMed ID: 35429247
[TBL] [Abstract][Full Text] [Related]
32. Correlation between sclerostin and Dickkopf-1 with aortic arterial stiffness in patients with type 2 diabetes: A prospective, cross-sectional study.
Yang HY; Wu DA; Chen MC; Hsu BG
Diab Vasc Dis Res; 2019 May; 16(3):281-288. PubMed ID: 30547685
[TBL] [Abstract][Full Text] [Related]
33. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover.
van Lierop AH; Hamdy NA; Hamersma H; van Bezooijen RL; Power J; Loveridge N; Papapoulos SE
J Bone Miner Res; 2011 Dec; 26(12):2804-11. PubMed ID: 21786318
[TBL] [Abstract][Full Text] [Related]
34. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
[TBL] [Abstract][Full Text] [Related]
35. Increased levels of Dickkopf-1 are indicative of Wnt/β-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density.
Tsentidis C; Gourgiotis D; Kossiva L; Marmarinos A; Doulgeraki A; Karavanaki K
Osteoporos Int; 2017 Mar; 28(3):945-953. PubMed ID: 27766367
[TBL] [Abstract][Full Text] [Related]
36. Suppression of Sclerostin and Dickkopf-1 levels in patients with fluorine bone injury.
Wang W; Xu J; Liu K; Liu X; Li C; Cui C; Zhang Y; Li H
Environ Toxicol Pharmacol; 2013 May; 35(3):402-7. PubMed ID: 23467116
[TBL] [Abstract][Full Text] [Related]
37. Sclerostin levels and changes in bone metabolism after bariatric surgery.
Muschitz C; Kocijan R; Marterer C; Nia AR; Muschitz GK; Resch H; Pietschmann P
J Clin Endocrinol Metab; 2015 Mar; 100(3):891-901. PubMed ID: 25490275
[TBL] [Abstract][Full Text] [Related]
38. Circulating Wnt/β-catenin signalling inhibitors and uraemic vascular calcifications.
Yang CY; Chang ZF; Chau YP; Chen A; Yang WC; Yang AH; Lee OK
Nephrol Dial Transplant; 2015 Aug; 30(8):1356-63. PubMed ID: 25817223
[TBL] [Abstract][Full Text] [Related]
39. In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls.
Fassio A; Idolazzi L; Viapiana O; Benini C; Vantaggiato E; Bertoldo F; Rossini M; Gatti D
Clin Rheumatol; 2017 Oct; 36(10):2377-2381. PubMed ID: 28634697
[TBL] [Abstract][Full Text] [Related]
40. The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus.
Gaudio A; Privitera F; Pulvirenti I; Canzonieri E; Rapisarda R; Fiore CE
Diab Vasc Dis Res; 2014 Jan; 11(1):48-52. PubMed ID: 24227537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
